Alpelisib (BYL719) vs Inavolisib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: PI3K-alpha · full HR+/HER2- Metastatic Breast Cancer pipeline
Alpelisib (BYL719)
Marketed by Novartis
NCT02437318 · Phase 3 · completed
This was a randomized, triple-blind, placebo-controlled trial with 572 participants. The primary clinical endpoint, investigator-assessed progression-free survival in the PIK3CA-mutant cohort, was met: median progression-free survival was 11.0 versus 5.7 months, with a hazard ratio of 0.65 and one-sided p=0.00065.
Next expected readout: December 2026 · NCT05563220 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36) (met)
Result source: NCT02437318
Inavolisib · Itovebi
Marketed by Roche
NCT04191499 · Phase 2/3 · active, not recruiting
Participants were randomly assigned 1:1 and both participants and investigators were masked, with a placebo plus palbociclib and fulvestrant comparator and 325 participants. The primary endpoint, progression-free survival, favored inavolisib with a hazard ratio of 0.43 (95% CI 0.32 to 0.59, p<0.0001), so it was met.
Next expected readout: December 2026 · NCT03006172 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) (Up to 3.7 years): Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3) (met)
Result source: NCT04191499
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Alpelisib (BYL719) | Inavolisib |
|---|---|---|
| PFS, median | 11 vs 5.7+5.3 vs placeboNCT024373187 other results
| 15 vs 7.3+7.7 vs placeboNCT04191499 |
| OS, median | 39.3 vs 31.4+7.9 vs placeboNCT024373184 other results
| —Trial running · NCT04191499 |
| ORR | 26.6% vs 13.4%+13.2 vs placeboNCT024373184 other results
| —Trial running · NCT04191499 |
| Clinical benefit rate | 61.5% vs 44.8%+16.7 vs placeboNCT024373184 other results
| —Trial running · NCT04191499 |
PFS, median
- Alpelisib (BYL719)
- 11 vs 5.7+5.3 vs placeboNCT02437318
7 other results
- 7.4 vs 7.2 NCT02437318
- 10.9 vs 7.4 NCT02437318
- 9 vs 7.4 NCT02437318
- 11.0 vs 5.7 NCT02437318
- 8 NCT03056755
- 5.6 NCT03056755
- 5.6 NCT03056755
- Inavolisib
- 15 vs 7.3+7.7 vs placeboNCT04191499
OS, median
- Alpelisib (BYL719)
- 39.3 vs 31.4+7.9 vs placeboNCT02437318
4 other results
- 37.3 vs 34.3 NCT02437318
- 27.3 NCT03056755
- 29 NCT03056755
- 20.7 NCT03056755
- Inavolisib
- —Trial running · NCT04191499
ORR
- Alpelisib (BYL719)
- 26.6% vs 13.4%+13.2 vs placeboNCT02437318
4 other results
- 20.9% vs 13.4% NCT02437318
- 19.3% NCT03056755
- 17.5% NCT03056755
- 25.2% NCT03056755
- Inavolisib
- —Trial running · NCT04191499
Clinical benefit rate
- Alpelisib (BYL719)
- 61.5% vs 44.8%+16.7 vs placeboNCT02437318
4 other results
- 53.9% vs 44.8% NCT02437318
- 46.2% NCT03056755
- 35.1% NCT03056755
- 38.3% NCT03056755
- Inavolisib
- —Trial running · NCT04191499
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Alpelisib (BYL719): 4 of 4 rows · Inavolisib: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Alpelisib (BYL719) | Inavolisib |
|---|---|---|
| Dropout rate | n/a: no completion milestonea NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 25 more results47.5% NCT05631795 · Phase 4 · registry result, not featured evidence · combination 99.2%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 100%Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 92.1%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 0%Cohort 2: Zotatifin in Combination NCT05101564 · Phase 2 · registry result, not featured evidence · combination 14.3%Cohort 3:Zotatifin in Combination NCT05101564 · Phase 2 · registry result, not featured evidence · combination —350 mg BYL-719/Alpelisib NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination —300 mg BYL-719/Alpelisib NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination 0%250 mg BYL-719/Alpelisib NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination 0%BYL-719 (Alpelisib) Dose Expansion NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination 0%DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%DOSE FINDING PHASE, Arm B, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 33.3%300mg BYL719, 3.6mg/kg T-DM1 NCT02038010 · Phase 1 · registry result, not featured evidence · combination 9.1%250mg BYL719, 3.6mg/kg T-DM1 NCT02038010 · Phase 1 · registry result, not featured evidence · combination | n/a: no completion milestone NCT04191499 · Phase 2/3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 2/3 |
| Discontinued due to AEs | 4.9%a NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 25 more results10% NCT05631795 · Phase 4 · registry result, not featured evidence · combination 15.7%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 11.1%Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 10.3%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort 2: Zotatifin in Combination NCT05101564 · Phase 2 · registry result, not featured evidence · combination —Cohort 3:Zotatifin in Combination NCT05101564 · Phase 2 · registry result, not featured evidence · combination —350 mg BYL-719/Alpelisib NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination —300 mg BYL-719/Alpelisib NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination —250 mg BYL-719/Alpelisib NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination —BYL-719 (Alpelisib) Dose Expansion NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination —DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —DOSE FINDING PHASE, Arm B, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —300mg BYL719, 3.6mg/kg T-DM1 NCT02038010 · Phase 1 · registry result, not featured evidence · combination —250mg BYL719, 3.6mg/kg T-DM1 NCT02038010 · Phase 1 · registry result, not featured evidence · combination | 0.6% NCT04191499 · Phase 2/3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 2/3 |
| Serious AEs | 38.7%a NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 25 more results25% NCT05631795 · Phase 4 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 29.1%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 0%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 38.1%Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 30.2%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 30%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 0%Cohort 2: Zotatifin in Combination NCT05101564 · Phase 2 · registry result, not featured evidence · combination 0%Cohort 3:Zotatifin in Combination NCT05101564 · Phase 2 · registry result, not featured evidence · combination 0%350 mg BYL-719/Alpelisib NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination 0%300 mg BYL-719/Alpelisib NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination 0%250 mg BYL-719/Alpelisib NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination 0%BYL-719 (Alpelisib) Dose Expansion NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination 0%DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 25%DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 57.1%DOSE FINDING PHASE, Arm B, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 50%Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 33.3%Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 16.7%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 28.6%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 50%300mg BYL719, 3.6mg/kg T-DM1 NCT02038010 · Phase 1 · registry result, not featured evidence · combination 27.3%250mg BYL719, 3.6mg/kg T-DM1 NCT02038010 · Phase 1 · registry result, not featured evidence · combination | 24.1% NCT04191499 · Phase 2/3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 2/3 |
| Most frequent reported AEs | a hyperglycaemia 64.1% (placebo 9.4%) diarrhoea 58.8% (placebo 16.7%) nausea 46.8% (placebo 22.3%) NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 22 more resultshyperglycaemia 90% stomatitis 37.5% diarrhoea 35% NCT05631795 · Phase 4 · registry result, not featured evidence · combination diarrhoea 64.6% hyperglycaemia 59.8% nausea 46.5% NCT03056755 · Phase 2 · registry result, not featured evidence · combination asthenia 100% blood creatinine increased 100% diarrhoea 100% NCT03056755 · Phase 2 · registry result, not featured evidence · combination diarrhoea 68.3% hyperglycaemia 64.3% nausea 54% NCT03056755 · Phase 2 · registry result, not featured evidence · combination hyperglycaemia 67.5% diarrhoea 54% nausea 40.5% NCT03056755 · Phase 2 · registry result, not featured evidence · combination diarrhoea 70% hyperglycaemia 60% fatigue 50% NCT03056755 · Phase 2 · registry result, not featured evidence · combination aspartate aminotransferase increased 50% breast pain 50% cpk increased 50% NCT05101564 · Phase 2 · registry result, not featured evidence · combination fatigue 71.4% headache 42.9% nausea 42.9% NCT05101564 · Phase 2 · registry result, not featured evidence · combination 350 mg BYL-719/Alpelisib hyperglycemia 100% diarrhea 85.7% electrolyte imbalance 71.4% NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination 300 mg BYL-719/Alpelisib diarrhea 100% electrolyte imbalance 100% fatigue 100% NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination 250 mg BYL-719/Alpelisib anemia 100% nausea 100% diarrhea 66.7% NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination nausea 66.7% diarrhea 63.3% hyperglycemia 63.3% NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination rash maculo-papular 33.3% abdominal pain 0% alanine aminotransferase increased 0% NCT01870505 · Phase 1 · registry result, not featured evidence · combination rash maculo-papular 50% abdominal pain 25% alkaline phosphatase increased 25% NCT01870505 · Phase 1 · registry result, not featured evidence · combination aspartate aminotransferase increased 28.6% abdominal pain 14.3% blood bilirubin increased 14.3% NCT01870505 · Phase 1 · registry result, not featured evidence · combination rash maculo-papular 33.3% confusion 16.7% lymphocyte count decreased 16.7% NCT01870505 · Phase 1 · registry result, not featured evidence · combination lymphocyte count decreased 33.3% rash maculo-papular 33.3% anemia 16.7% NCT01870505 · Phase 1 · registry result, not featured evidence · combination abdominal pain 0% alanine aminotransferase increased 0% alkaline phosphatase increased 0% NCT01870505 · Phase 1 · registry result, not featured evidence · combination aspartate aminotransferase increased 33.3% rash maculo-papular 33.3% alkaline phosphatase increased 16.7% NCT01870505 · Phase 1 · registry result, not featured evidence · combination lymphocyte count decreased 42.9% neutrophil count decreased 42.9% white blood cell decreased 42.9% NCT01870505 · Phase 1 · registry result, not featured evidence · combination 300mg BYL719, 3.6mg/kg T-DM1 aspartate aminotransferase increased 83.3% fatigue 83.3% hypoalbuminemia 83.3% NCT02038010 · Phase 1 · registry result, not featured evidence · combination 250mg BYL719, 3.6mg/kg T-DM1 aspartate aminotransferase increased 90.9% hyperglycemia 81.8% peripheral sensory neuropathy 81.8% NCT02038010 · Phase 1 · registry result, not featured evidence · combination | neutropenia 54.3% (placebo 54.9%) hyperglycaemia 53.7% (placebo 7.4%) diarrhoea 48.1% (placebo 16%) NCT04191499 · Phase 2/3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 2/3 |
Notes
- aPopulation comparability has not been reviewed for 25 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Alpelisib (BYL719)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 17 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
+ 6 further endpoints in the CSV export.
Breast Cancer
Shared mechanism: PI3K-alpha · full Breast Cancer pipeline
Alpelisib (BYL719)
Marketed by Novartis
NCT02437318 · Phase 3 · completed
This was a randomized, triple-blind, placebo-controlled trial with 572 participants. The primary clinical endpoint, investigator-assessed progression-free survival in the PIK3CA-mutant cohort, was met: median progression-free survival was 11.0 versus 5.7 months, with a hazard ratio of 0.65 and one-sided p=0.00065.
Next expected readout: December 2026 · NCT05563220 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36) (met)
Result source: NCT02437318
Inavolisib · Itovebi
Marketed by Roche
NCT04191499 · Phase 2/3 · active, not recruiting
Participants were randomly assigned 1:1 and both participants and investigators were masked, with a placebo plus palbociclib and fulvestrant comparator and 325 participants. The primary endpoint, progression-free survival, favored inavolisib with a hazard ratio of 0.43 (95% CI 0.32 to 0.59, p<0.0001), so it was met.
Next expected readout: December 2026 · NCT07245797 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) (Up to 3.7 years): Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3) (met)
Result source: NCT04191499
Results for Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Alpelisib (BYL719): 5 of 5 rows · Inavolisib: 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Alpelisib (BYL719) | Inavolisib |
|---|---|---|
| PFS time to event · months | 11 vs 5.7 placebo monthsa,b,c,d NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 4 more doses10.97 vs 5.65 placebo months NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 10.9 vs 3.7 placebo months NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 7.43 vs 7.23 placebo months NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 9 vs 3.7 placebo months NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 15 vs 7.3 placebo monthsb,c,d NCT04191499 · Phase 2/3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 2/3 |
| Dropout rate | n/a: no completion milestonee NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 26 more results47.5% NCT05631795 · Phase 4 · registry result, not featured evidence · combination 99.2%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 100%Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 92.1%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 0%Cohort 2: Zotatifin in Combination NCT05101564 · Phase 2 · registry result, not featured evidence · combination 14.3%Cohort 3:Zotatifin in Combination NCT05101564 · Phase 2 · registry result, not featured evidence · combination 28.2% NCT01923168 · Phase 2 · registry result, not featured evidence · combination —350 mg BYL-719/Alpelisib NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination —300 mg BYL-719/Alpelisib NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination 0%250 mg BYL-719/Alpelisib NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination 0%BYL-719 (Alpelisib) Dose Expansion NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination 0%DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%DOSE FINDING PHASE, Arm B, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 33.3%300mg BYL719, 3.6mg/kg T-DM1 NCT02038010 · Phase 1 · registry result, not featured evidence · combination 9.1%250mg BYL719, 3.6mg/kg T-DM1 NCT02038010 · Phase 1 · registry result, not featured evidence · combination | n/a: no completion milestone NCT04191499 · Phase 2/3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 2/3 |
| Discontinued due to AEs | 4.9%e NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 26 more results10% NCT05631795 · Phase 4 · registry result, not featured evidence · combination 15.7%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 11.1%Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 10.3%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort 2: Zotatifin in Combination NCT05101564 · Phase 2 · registry result, not featured evidence · combination —Cohort 3:Zotatifin in Combination NCT05101564 · Phase 2 · registry result, not featured evidence · combination 9.2% NCT01923168 · Phase 2 · registry result, not featured evidence · combination —350 mg BYL-719/Alpelisib NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination —300 mg BYL-719/Alpelisib NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination —250 mg BYL-719/Alpelisib NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination —BYL-719 (Alpelisib) Dose Expansion NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination —DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —DOSE FINDING PHASE, Arm B, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —300mg BYL719, 3.6mg/kg T-DM1 NCT02038010 · Phase 1 · registry result, not featured evidence · combination —250mg BYL719, 3.6mg/kg T-DM1 NCT02038010 · Phase 1 · registry result, not featured evidence · combination | 0.6% NCT04191499 · Phase 2/3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 2/3 |
| Serious AEs | 38.7%e NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 26 more results25% NCT05631795 · Phase 4 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 29.1%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 0%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 38.1%Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 30.2%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 30%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 0%Cohort 2: Zotatifin in Combination NCT05101564 · Phase 2 · registry result, not featured evidence · combination 0%Cohort 3:Zotatifin in Combination NCT05101564 · Phase 2 · registry result, not featured evidence · combination 16.2% NCT01923168 · Phase 2 · registry result, not featured evidence · combination 0%350 mg BYL-719/Alpelisib NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination 0%300 mg BYL-719/Alpelisib NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination 0%250 mg BYL-719/Alpelisib NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination 0%BYL-719 (Alpelisib) Dose Expansion NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination 0%DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 25%DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 57.1%DOSE FINDING PHASE, Arm B, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 50%Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 33.3%Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 16.7%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 28.6%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 50%300mg BYL719, 3.6mg/kg T-DM1 NCT02038010 · Phase 1 · registry result, not featured evidence · combination 27.3%250mg BYL719, 3.6mg/kg T-DM1 NCT02038010 · Phase 1 · registry result, not featured evidence · combination | 24.1% NCT04191499 · Phase 2/3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 2/3 |
| Most frequent reported AEs | e hyperglycaemia 64.1% (placebo 9.4%) diarrhoea 58.8% (placebo 16.7%) nausea 46.8% (placebo 22.3%) NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 23 more resultshyperglycaemia 90% stomatitis 37.5% diarrhoea 35% NCT05631795 · Phase 4 · registry result, not featured evidence · combination diarrhoea 64.6% hyperglycaemia 59.8% nausea 46.5% NCT03056755 · Phase 2 · registry result, not featured evidence · combination asthenia 100% blood creatinine increased 100% diarrhoea 100% NCT03056755 · Phase 2 · registry result, not featured evidence · combination diarrhoea 68.3% hyperglycaemia 64.3% nausea 54% NCT03056755 · Phase 2 · registry result, not featured evidence · combination hyperglycaemia 67.5% diarrhoea 54% nausea 40.5% NCT03056755 · Phase 2 · registry result, not featured evidence · combination diarrhoea 70% hyperglycaemia 60% fatigue 50% NCT03056755 · Phase 2 · registry result, not featured evidence · combination aspartate aminotransferase increased 50% breast pain 50% cpk increased 50% NCT05101564 · Phase 2 · registry result, not featured evidence · combination fatigue 71.4% headache 42.9% nausea 42.9% NCT05101564 · Phase 2 · registry result, not featured evidence · combination hyperglycaemia 53.1% (placebo 6.4%) diarrhoea 50.8% (placebo 15.2%) rash 44.6% (placebo 8%) NCT01923168 · Phase 2 · registry result, not featured evidence · combination 350 mg BYL-719/Alpelisib hyperglycemia 100% diarrhea 85.7% electrolyte imbalance 71.4% NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination 300 mg BYL-719/Alpelisib diarrhea 100% electrolyte imbalance 100% fatigue 100% NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination 250 mg BYL-719/Alpelisib anemia 100% nausea 100% diarrhea 66.7% NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination nausea 66.7% diarrhea 63.3% hyperglycemia 63.3% NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination rash maculo-papular 33.3% abdominal pain 0% alanine aminotransferase increased 0% NCT01870505 · Phase 1 · registry result, not featured evidence · combination rash maculo-papular 50% abdominal pain 25% alkaline phosphatase increased 25% NCT01870505 · Phase 1 · registry result, not featured evidence · combination aspartate aminotransferase increased 28.6% abdominal pain 14.3% blood bilirubin increased 14.3% NCT01870505 · Phase 1 · registry result, not featured evidence · combination rash maculo-papular 33.3% confusion 16.7% lymphocyte count decreased 16.7% NCT01870505 · Phase 1 · registry result, not featured evidence · combination lymphocyte count decreased 33.3% rash maculo-papular 33.3% anemia 16.7% NCT01870505 · Phase 1 · registry result, not featured evidence · combination abdominal pain 0% alanine aminotransferase increased 0% alkaline phosphatase increased 0% NCT01870505 · Phase 1 · registry result, not featured evidence · combination aspartate aminotransferase increased 33.3% rash maculo-papular 33.3% alkaline phosphatase increased 16.7% NCT01870505 · Phase 1 · registry result, not featured evidence · combination lymphocyte count decreased 42.9% neutrophil count decreased 42.9% white blood cell decreased 42.9% NCT01870505 · Phase 1 · registry result, not featured evidence · combination 300mg BYL719, 3.6mg/kg T-DM1 aspartate aminotransferase increased 83.3% fatigue 83.3% hypoalbuminemia 83.3% NCT02038010 · Phase 1 · registry result, not featured evidence · combination 250mg BYL719, 3.6mg/kg T-DM1 aspartate aminotransferase increased 90.9% hyperglycemia 81.8% peripheral sensory neuropathy 81.8% NCT02038010 · Phase 1 · registry result, not featured evidence · combination | neutropenia 54.3% (placebo 54.9%) hyperglycaemia 53.7% (placebo 7.4%) diarrhoea 48.1% (placebo 16%) NCT04191499 · Phase 2/3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 2/3 |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2/3 versus Phase 3.
- cPopulation context differs: prior_therapy differs (naive versus experienced).
- dThe assessment timepoint is not available for both results.
- ePopulation comparability has not been reviewed for 26 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Alpelisib (BYL719)
show 1 more result
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 17 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
+ 9 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alpelisib (BYL719)'s landscape · Inavolisib's landscape